Tratamiento de la osteoporosis: novedades
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Deutschmann HA, Weger M, Weger W,Kotanko P, Deutschmann MJ, Skrabal F. Searchfor occult secondary osteoporosis: impact ofidentified possible risk factors on bone mineraldensity. J Intern Med 2002;252(5):389-97. DOI: https://doi.org/10.1046/j.1365-2796.2002.01040.x
Tannenbaum C, Clark J, Schwartzman K,Wallenstein S, Lapinski R, Meier D, et al. Yieldof laboratory testing to identify secondarycontributors to osteoporosis in otherwisehealthy women. J Clin Endocrinol Metab2002;87(10):4431-7. DOI: https://doi.org/10.1210/jc.2002-020275
Guelman R, Plantalech L. Osteoporosissecundarias en una población de pacientesevaluadas por osteopenia/osteoporosis, 2001.Diagnóstico en Osteología 2001;2(5):12-8.
Orwoll E, Klein R. Osteoporosis in men. 2nded. San Diego, CA: Academic Press, 2001. DOI: https://doi.org/10.1016/B978-012470862-4/50043-X
Kanis JA. Assessment of fracture risk andits application to screening for postmenopausalosteoporosis: synopsis of a WHO report. WHOStudy Group. Osteoporos Int 1994;4(6):368-81. DOI: https://doi.org/10.1007/BF01622200
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineraldensity predict occurrence of osteoporoticfractures. BMJ 1996;312(7041):1254-9. DOI: https://doi.org/10.1136/bmj.312.7041.1254
Delmas PD. Treatment of postmenopausalosteoporosis. Lancet 2002;359(9322):2018-26. DOI: https://doi.org/10.1016/S0140-6736(02)08827-X
Eastell R, Barton I, Hannon RA, Chines A,Garnero P, Delmas PD. Relationship of earlychanges in bone resorption to the reduction infracture risk with risedronate. J Bone Miner Res2003;18(6):1051-6. DOI: https://doi.org/10.1359/jbmr.2003.18.6.1051
Garnero P, Sornay-Rendu E, Chapuy MC,Delmas PD. Increased bone turnover in latepostmenopausal women is a major determinantof osteoporosis. J Bone Miner Res 1996Mar;11(3):337-49. DOI: https://doi.org/10.1002/jbmr.5650110307
Kanis JA, Johnell O, Oden A, Dawson A,De Laet C, Jonsson B. Ten year probabilitiesof osteoporotic fractures according to BMD anddiagnostic thresholds. Osteoporos Int2001;12(12):989-95. DOI: https://doi.org/10.1007/s001980170006
Asociación Argentina de Osteología yMetabolismo Mineral. Consenso SAO-AAOMM, 2004. Disponible en: URL: http//:www.aaomm.org.ar.
Riggs BL, Parfitt AM. Drugs used to treatosteoporosis: the critical need for a uniformnomenclature based on their action on boneremodeling. J Bone Miner Res 2005;20(2):177-84. DOI: https://doi.org/10.1359/JBMR.041114
Russell RG. Ibandronate: pharmacologyand preclinical studies. Bone 2006;38(4 Suppl1):S7-12. DOI: https://doi.org/10.1016/j.bone.2006.01.151
Black D, Cliff R. Biphosphonates for theprevention and treatment of osteoporosis. En:Favus MJ, editor, et al. Primer on the metabolicbone disease and disorders of mineralmetabolism. 6th ed. Washington, DC: AmericanSociety for Bone and Mineral Research, 2006.Cap. 50.
Fromm GA, Vega E, Plantalech L, GalichAM, Mautalen CA. Differential action ofpamidronate on trabecular and cortical bone inwomen with involutional osteoporosis.Osteoporos Int 1991;1(3):129-33. DOI: https://doi.org/10.1007/BF01625440
Black DM, Cummings SR, Karpf DB,Cauley JA, Thompson DE, Nevitt MC, et al.Randomised trial of effect of alendronate onrisk of fracture in women with existing vertebralfractures. Fracture Intervention Trial ResearchGroup. Lancet 1996;348(9041):1535-41. DOI: https://doi.org/10.1016/S0140-6736(96)07088-2
Saag KG, Emkey R, Schnitzer TJ, BrownJP, Hawkins F, Goemaere S, et al. Alendronatefor the prevention and treatment ofglucocorticoid-induced osteoporosis.Glucocorticoid-Induced OsteoporosisIntervention Study Group. N Engl J Med1998;339(5):292-9.
Orwoll E, Ettinger M, Weiss S, Miller P,Kendler D, Graham J, et al. Alendronate forthe treatment of osteoporosis in men. N Engl JMed 2000;343(9):604-10. DOI: https://doi.org/10.1056/NEJM200008313430902
Harris ST, Watts NB, Genant HK,McKeever CD, Hangartner T, Keller M,et al.Effects of risedronate treatment on vertebral andnonvertebral fractures in women withpostmenopausal osteoporosis: a randomizedcontrolled trial. Vertebral Efficacy WithRisedronate Therapy (VERT) Study Group.JAMA 1999;282(14):1344-52. DOI: https://doi.org/10.1001/jama.282.14.1344
Reginster J, Minne HW, Sorensen OH,Hooper M, Roux C, Brandi ML, et al.Randomized trial of the effects of risedronateon vertebral fractures in women withestablished postmenopausal osteoporosis.Vertebral Efficacy with Risedronate Therapy(VERT) Study Group. Osteoporos Int2000;11(1):83-91. DOI: https://doi.org/10.1007/s001980050010
McClung MR, Geusens P, Miller PD, ZippelH, Bensen WG, Roux C, et al. Effect ofrisedronate on the risk of hip fracture in elderlywomen. Hip Intervention Program StudyGroup. N Engl J Med. 2001 Feb 1;344(5):333-40. DOI: https://doi.org/10.1056/NEJM200102013440503
Cohen S, Levy RM, Keller M, Boling E,Emkey RD, Greenwald M, et al. Risedronatetherapy prevents corticosteroid-induced boneloss: a twelve-month, multicenter, randomized,double-blind, placebo-controlled, parallel-group study. Arthritis Rheum1999;42(11):2309-18. DOI: https://doi.org/10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
Chesnut III CH, Skag A, Christiansen C,Recker R, Stakkestad JA, Hoiseth A, et al.Effects of oral ibandronate administered dailyor intermittently on fracture risk inpostmenopausal osteoporosis. J Bone MinerRes 2004;19(8):1241-9. DOI: https://doi.org/10.1359/JBMR.040325
Miller PD, McClung MR, Macovei L,Stakkestad JA, Luckey M, Bonvoisin B,et al.Monthly oral ibandronate therapy inpostmenopausal osteoporosis: 1-year resultsfrom the MOBILE study. J Bone Miner Res2005;20(8):1315-22. DOI: https://doi.org/10.1359/JBMR.050313
Peretz A, Body JJ, Dumon JC, RozenbergS, Hotimski A, Praet JP, et al. Cyclicalpamidronate infusions in postmenopausalosteoporosis. Maturitas 1996;25(1):69-75. DOI: https://doi.org/10.1016/0378-5122(96)01118-8
Bolognese M, Reid DM, Langdahl B,Hughes C, Ward P, Masanauskaite D, et al.Efficacy of intravenous ibandronate injectionsin postmenopausal osteoporosis: 1 year findingfor DIVA. J Bone Miner Res 2005; 20(suppl1): s96. [abstract].
Reid IR, Brown JP, Burckhardt P, HorowitzZ, Richardson P, Trechsel U,et al. Intravenouszoledronic acid in postmenopausal women withlow bone mineral density. N Engl J Med2002;346(9):653-61.
Chesnut CH 3rd, Silverman S, Andriano K,Genant H, Gimona A, Harris S, et al. Arandomized trial of nasal spray salmoncalcitonin in postmenopausal women withestablished osteoporosis: the prevent recurrenceof osteoporotic fractures study. PROOF StudyGroup. Am J Med 2000;109(4):267-76. DOI: https://doi.org/10.1016/S0002-9343(00)00490-3
Overgaard K, Hansen MA, Jensen SB,Christiansen C. Effect of salcatonin givenintranasally on bone mass and fracture rates inestablished osteoporosis: a dose-response study.BMJ 1992;305(6853):556-61. DOI: https://doi.org/10.1136/bmj.305.6853.556
Lindsay R, Hart DM, Forrest C, Baird C.Prevention of spinal osteoporosis inoophorectomised women. Lancet1980;2(8205):1151-4. DOI: https://doi.org/10.1016/S0140-6736(80)92592-1
Munk-Jensen N, Pors Nielsen S, Obel EB,Bonne Eriksen P. Reversal of postmenopausalvertebral bone loss by oestrogen andprogestogen: adouble blind placebo controlled study. Br MedJ (Clin Res Ed) 1988;296(6630):1150-2. DOI: https://doi.org/10.1136/bmj.296.6630.1150
Cauley JA, Seeley DG, Ensrud K, EttingerB, Black D, Cummings SR. Estrogenreplacement therapy and fractures in olderwomen. Study of Osteoporotic FracturesResearch Group. Ann Intern Med1995;122(1):9-16. DOI: https://doi.org/10.7326/0003-4819-122-1-199501010-00002
Cauley JA, Robbins J, Chen Z, CummingsSR, Jackson RD, LaCroix AZ, et al. Effects ofestrogen plus progestin on risk of fracture andbone mineral density: the Women’s HealthInitiative randomized trial. JAMA2003;290(13):1729-38. DOI: https://doi.org/10.1001/jama.290.13.1729
Rossouw JE, Anderson GL, Prentice RL,LaCroix AZ, Kooperberg C, Stefanick ML, etal. Risks and benefits of estrogen plus progestinin healthy postmenopausal women: principalresults From the Women’s Health Initiativerandomized controlled trial. JAMA2002;288(3):321-33. DOI: https://doi.org/10.1001/jama.288.3.321
Prestwood KM, Kenny AM, Unson C,Kulldorff M. The effect of low dose micronized17ss-estradiol on bone turnover, sex hormonelevels, and side effects in older women: arandomized, double blind, placebo-controlledstudy. J Clin Endocrinol Metab2000;85(12):4462-9. DOI: https://doi.org/10.1210/jcem.85.12.7001
Lindsay R, Gallagher JC, Kleerekoper M,Pickar JH. Effect of lower doses of conjugatedequine estrogens with and withoutmedroxyprogesterone acetate on bone in earlypostmenopausal women. JAMA2002;287(20):2668-76.
Elders PJ, Netelenbos JC, Lips P, vanGinkel FC, Khoe E, Leeuwenkamp OR,et al.Calcium supplementation reduces vertebralbone loss in perimenopausal women: acontrolled trial in 248 women between 46 and55 years of age. J Clin Endocrinol Metab1991;73(3):533-40. DOI: https://doi.org/10.1210/jcem-73-3-533
Parfitt AM, Gallagher JC, Heaney RP,Johnston CC, Neer R, Whedon GD. Vitamin Dand bone health in the elderly. Am J Clin Nutr1982;36(5 Suppl):1014-31. DOI: https://doi.org/10.1093/ajcn/36.5.1014
McKenna MJ, Freaney R. Secondaryhyperparathyroidism in the elderly: means todefining hypovitaminosis D. Osteoporos Int1998;8 Suppl 2:S3-6. DOI: https://doi.org/10.1007/PL00022725
Bischoff-Ferrari HA, Dietrich T, Orav EJ,Hu FB, Zhang Y, Karlson EW,et al. Higher 25-hydroxyvitamin D concentrations are associatedwith better lower-extremity function in bothactive and inactive persons aged > or =60 y.Am J Clin Nutr 2004;80(3):752-8. DOI: https://doi.org/10.1093/ajcn/80.3.752
Dietary Reference Intakes: calcium,phosphorous, magnesium, vitamin D andfluoride. Washington DC: National AcademicPress, 1997.
Dawson-Hughes B, Heaney RP, Holick MF,Lips P, Meunier PJ, Vieth R. Estimates ofoptimal vitamin D status. Osteoporos Int2005;16(7):713-6. DOI: https://doi.org/10.1007/s00198-005-1867-7
Armas LA, Hollis BW, Heaney RP. VitaminD2 is much less effective than vitamin D3 inhumans. J Clin Endocrinol Metab2004;89(11):5387-91 DOI: https://doi.org/10.1210/jc.2004-0360
Plantalech L, Oliveri B, Salerni H, PozzoMJ, et al. Hipovitaminosis D en adultosmayores habitantes de Buenos Aires.Actualizaciones en Osteología 2005;1:47-54
Oliveri B, Plantalech L, Bagur A, WittichAC, Rovai G, Pusiol E, et al. High prevalenceof vitamin D insufficiency in healthy elderlypeople living at home in Argentina. Eur J ClinNutr 2004;58(2):337-42. DOI: https://doi.org/10.1038/sj.ejcn.1601786
Plantalech L, Knoblovits P, Cambiazzo E,Balzaretti M, Oyamburu J, Bonetto A, et al.Hipovitaminosis D en ancianosinstitucionalizados de Buenos Aires. Medicina(B Aires) 1997;57(1):29-35.
Grant AM, Avenell A, Campbell MK,McDonald AM, MacLennan GS, McPhersonGC,et al. Oral vitamin D3 and calcium forsecondary prevention of low-trauma fracturesin elderly people (Randomised Evaluation ofCalcium Or vitamin D, RECORD): arandomised placebo-controlled trial. Lancet2005;365(9471):1621-8. DOI: https://doi.org/10.1016/S0140-6736(05)63013-9
Jackson RD, LaCroix AZ, Gass M, WallaceRB, Robbins J, Lewis CE, et al. Calcium plusvitamin D supplementation and the risk offractures. N Engl J Med 2006;354(7):669-83.Errata en: N Engl J Med 2006;354(10):1102. DOI: https://doi.org/10.1056/NEJMx060015
Neer RM, Arnaud CD, Zanchetta JR, PrinceR, Gaich GA, Reginster JY, et al. Effect ofparathyroid hormone (1-34) on fractures andbone mineral density in postmenopausal womenwith osteoporosis. N Engl J Med2001;344(19):1434-41. DOI: https://doi.org/10.1056/NEJM200105103441904
Hodsman AB, Hanley DA, Ettinger MP,Bolognese MA, Fox J, Metcalfe AJ,et al.Efficacy and safety of human parathyroidhormone-(1-84) in increasing bone mineraldensity in postmenopausal osteoporosis. J ClinEndocrinol Metab 2003;88(11):5212-20. DOI: https://doi.org/10.1210/jc.2003-030768
Cosman F. PTH treatment for osteoporosis.En: Favus MJ, editor, et al. Primer on themetabolic bone disease and disorders of mineralmetabolism. 6th ed. Washington, DC: AmericanSociety for Bone and Mineral Research, 2006.Cap. 52.
Marie PJ. Strontium ranelate: a dual modeof action rebalancing bone turnover in favourof bone formation. Curr Opin Rheumatol2006;18 Suppl 1:S11-5. DOI: https://doi.org/10.1097/01.bor.0000229522.89546.7b
Marie PJ. Strontium ranelate: aphysiological approach for optimizing boneformation and resorption. Bone 2006;38(2Suppl 1):S10-4. DOI: https://doi.org/10.1016/j.bone.2005.07.029
Ammann P. Strontium ranelate: aphysiological approach for an improved bonequality. Bone 2006;38(2 Suppl 1):15-8. DOI: https://doi.org/10.1016/j.bone.2005.09.023
Meunier PJ, Roux C, Seeman E, OrtolaniS, Badurski JE, Spector TD, et al. The effectsof strontium ranelate on the risk of vertebralfracture in women with postmenopausalosteoporosis. N Engl J Med 2004;350(5):459-68. DOI: https://doi.org/10.1056/NEJMoa022436
Adami S. Protelos: nonvertebral and hipantifracture efficacy in postmenopausalosteoporosis. Bone 2006;38(2 Suppl 1):23-7. DOI: https://doi.org/10.1016/j.bone.2005.08.028
Seeman E, Vellas B, Benhamou C, AquinoJP, Semler J, Kaufman JM, et al. Strontiumranelate reduces the risk of vertebral andnonvertebral fractures in women eighty yearsof age and older. J Bone Miner Res2006;21(7):1113-20 DOI: https://doi.org/10.1359/jbmr.060404